Impact Of Medicare RDS Tax Estimates Clarified; Employers Withhold Judgment On Reform Law
This article was originally published in The Pink Sheet Daily
Executive Summary
The upcoming tax on the Medicare retiree drug subsidy will be less harmful to large employers than recent accounting figures from a number of firms would suggest, House Energy and Commerce Committee staff report April 14.
You may also be interested in...
Medicare RDS Tax May Prompt Employer Coverage Shifts, Focus On Rx Costs
Prescription drug coverage for millions of retirees currently provided by for-profit employer plans may change in the coming years as a result of the new tax on the Medicare retiree drug subsidy, signed into law as part of health reform March 23
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.